期刊
VACCINE
卷 26, 期 19, 页码 2335-2343出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.02.064
关键词
EHV-1; canine influenza; H3
资金
- NIAID NIH HHS [R21 AI061412-02, R21 AI061412, 5R21AI061412] Funding Source: Medline
- NIGMS NIH HHS [R01 GM080533, R01GM080533] Funding Source: Medline
In 2004, canine influenza virus (CIV) was identified as a respiratory pathogen of dogs for the first time and found to be closely related to H3N8 equine influenza virus (EIV). We generated a recombinant vectored vaccine that expresses H3 of a recent isolate of EIV using equine herpesvirus type 1 (EHV-1) as the delivery vehicle. This EHV-1 vectored vaccine exhibited robust and stable EIV H3 expression and induced a strong influenza virus-specific response in both mice and dogs upon intranasal. or subcutaneous administration. Furthermore, upon challenge with the recent CIV isolate A/canine/PA/10915-07, protection of vaccinated dogs could be demonstrated by a significant reduction in clinical. sings, and, more importantly, by a significant reduction in virus shedding. We concluded that the EHV-1/H3 recombinant vector can be a valuable alternative for protection of dogs against clinical. disease induced by CIV and can significantly reduce virus spread. (C) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据